The present invention is a mitochondria-targeted antioxidant prodrug useful for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. Antioxidant prodrugs of the invention are produced by modifying an antioxidant to a fatty acid so that the resulting prodrug is targeted to and activated by an enzyme of mitochondrial fatty acid beta-oxidation.
本发明是一种线粒体靶向
抗氧化剂前药,用于预防或治疗与线粒体氧化还原环境变化导致的线粒体功能障碍有关的疾病或病症。该发明的
抗氧化剂前药是通过将
抗氧化剂改性为
脂肪酸而产生的,从而使得产生的前药能够靶向并被线粒体
脂肪酸β-氧化酶激活。